

Corimmun Has Successfully Started a Phase I Clinical Trial with its Lead Compound COR-1

Martinsried/Munich, Germany, November 25, 2009 -- Corimmun GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of cardiovascular diseases, today announced the start of a Phase I clinical trial with its lead compound COR-1. First dosing was initiated on October 27. The first two dose groups (out of a total of five planned) have been well tolerated, no relevant side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete serum clearance within 60 minutes after administration.

The trial is designed as a mono-centric, randomized, single blind, placebo-controlled study, which is conducted in Germany. 50 male human volunteers between 18 and 45 years will receive COR-1 or matching placebo intravenously as single ascending doses. Primary endpoints are safety and tolerability, while the pharmacokinetics profile of COR-1 will be assessed as a secondary endpoint. Also pharmacodynamics will be studied.

"We are very much looking forward to the results of this trial," said Götz Münch, CEO of Corimmun. "The resulting data will provide a good basis to start a Phase IIa clinical trial with COR-1 in patients by next year."

"The first indication we are addressing is heart failure, which is a frequent disease and causes a large death toll" added Martin Ungerer, Medical Director of Corimmun.

COR-1 is a cyclic peptide with a unique mode of action. It is developed by Corimmun for the treatment of heart failure, by targeting the auto-immune mechanism of antibodies directed against the β 1-adrenergic receptor in these patients. COR-1 is a drug which prevents this auto-antibody-mediated propagation of heart failure. Functional auto-antibodies are an increasingly recognized phenomenon in any form of heart failure, corresponding to a large and currently unmet medical need.

In contrast to existing drugs used in the treatment of heart failure, COR-1 does not result in any acute negative effect on hemodynamics (such as lowering blood pressure or pulse rate) which often causes side effects with these existing drugs.

Notes to Editors

About COR-1:

Corimmun's lead product COR-1 is a cyclic peptide. It targets autoantibodies directed against the human β 1-adrenergic receptor. As a result, these auto-antibodies are inactivated and cardiac performance improves.

COR-1 has a short half-life. COR-1 has been validated in relevant animal models and has shown strong efficacy in terms of decrease of immune reaction and improvement of heart failure (clinical symptoms as well as hemodynamic parameters).

About Corimmun

Corimmun GmbH (www.corimmun.de) is a private biotechnology company located in Martinsried near Munich, Germany, which focuses on inflammatory mechanisms in heart failure and atherosclerosis. For these indications, Corimmun currently develops 4 projects in preclinical and clinical stage. The company receives constant scientific support from the outstanding university groups of the company's founders. In 2008, Corimmun successfully closed its Series A financing round, led by MIG Funds (www.mig.ag) with KfW, Bayern Kapital and High-Tech Fonds as Co-Investors.

Contact

Dr. Götz Münch, CEO Corimmun GmbH
Tel: +49-89-8565 2010
Email: muench@corimmun.com